Siric > Research > Institutes > Institute of Regenerative Medicine and Biotherapy (IRMB)


Institute of Regenerative Medicine and Biotherapy

CHRU Montpellier Hopital Saint-Eloi

80 avenue Augustin Fliche

34295 Montpellier cedex 05




Key Figures

126 people

210 publications between 2008-2012



The Institute of Regenerative Medicine and Biotherapy (IRMB) associates the University Hospital of Montpellier (CHU Montpellier), the INSERM and the University Montpellier I (UM1).

The aim of the IRMB is to develop cell or biological drugs in the field of regenerative medicine.

IRMB provides a complete chain of expertise associating fundamental research laboratories, hospital biology departments, and private companies. IRMB comprises 6 INSERM research laboratories hosting scientific teams after evaluation by AERES ( and INSERM.

The availability of human cells or tissues with all ethical rules through the university hospital, the close association with Montpellier fundamental research institutes, and the hosting of private companies are major criteria to attract high level scientists, to create new tools in biotherapy, to provide a high level training to students, and to create employment.

IRMB gathers up to 130 people (90 academic and 40 private company people) in a 2874 m2 building containing 6 INSERM fundamental research laboratories, 4 CHU translational research laboratories, and 5 laboratories for private companies around common technical platforms providing key technologies for state-of-the-art biotherapy research. IRMB is embedded in the large “Biology and Pathology Network” that gathers all hospital laboratories with common management of human and financial resources. IRMB is located in direct proximity to the Unit for Cell and Gene Therapy, the Department for Clinical Hematology and Biotherapy and the Clinical Investigation Center. The INSERM “Institute of Neurosciences is also closely located to the IRMB on the Hopital St. Eloi Campus and provides access to a common animal facility and bioimaging facilities that can be accessed through the Montpellier RIO imaging network (MRI). IRMB has a direct access to the University of Sciences and techniques of Montpellier (UM2) that is going to merge with Universities Montpellier I and III to form a unique University of Montpellier South of France (UMSF).

Research Themes

– Normal and malignant stem cells and Immunotherapy

– Early embryonic development, pluripotent and hepatocyte stem cells

Technology platforms

– Regional Cytométry platform- Montpellier -RIO Imaging

– Micro Away Facility with an Affymetrix DNA microarray platform

– Cell reprogramming platform SAFE-IPS

– Biomathématic and Bioinformatic Unit